ReviewCyborg and bionic systems (Washington, D.C.)2021
Challenges and Possibilities of Cell-Based Tissue-Engineered Vascular Grafts.
Review in Cyborg and bionic systems (Washington, D.C.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Biomimetic Vascular Scaffold with Seamless Electrospun Aligned Nanofiber Conduit and 3D-Printed Coil Reinforcement.Advanced healthcare materials · 2026Article
- Synthetic and Tissue-Engineered Vascular Grafts: Current Status, Emerging Technologies, and Clinical Prospects.Reviews in cardiovascular medicine · 2025Review
- Immunomodulation and Mechanical Characterization of Manuka Honey-Incorporated Near-Field Electrospun Bioresorbable Vascular Grafts.Bioengineering (Basel, Switzerland) · 2025Article
- Article
- Article
- Light-based 3D bioprinting techniques for illuminating the advances of vascular tissue engineering.Materials today. Bio · 2024Review
- Syndecan-4 Functionalization Reduces the Thrombogenicity of Engineered Vascular Biomaterials.Annals of biomedical engineering · 2024Article
- Biomimetic Approaches in Scaffold-Based Blood Vessel Tissue Engineering.Biomimetics (Basel, Switzerland) · 2024Review
- Advances in the Model Structure of In Vitro Vascularized Organ-on-a-Chip.Cyborg and bionic systems (Washington, D.C.) · 2024Article
- Prosthetic vascular grafts engineered to combat calcification: Progress and future directions.Biotechnology and bioengineering · 2023Review
- Vascular Grafts: Technology Success/Technology Failure.BME frontiers · 2023Review
- Updated Perspectives on Direct Vascular Cellular Reprogramming and Their Potential Applications in Tissue Engineered Vascular Grafts.Journal of functional biomaterials · 2022Review
- Cell pairing for biological analysis in microfluidic devices.Biomicrofluidics · 2022Review
- Linking the region-specific tissue microstructure to the biaxial mechanical properties of the porcine left anterior descending artery.Acta biomaterialia · 2022Article
- Robotic Intracellular Electrochemical Sensing for Adherent Cells.Cyborg and bionic systems (Washington, D.C.) · 2022Article
- Mitigating challenges and expanding the future of vascular tissue engineering-are we there yet?Frontiers in physiology · 2022Article
- Review
- Potential of Autologous Progenitor Cells and Decellularized Porcine Artery Matrix in Construction of Tissue-engineered Vascular Grafts.Organogenesis · 2021Article
- Optimization of the Fluidic-Based Assembly for Three-Dimensional Construction of Multicellular Hydrogel Micro-Architecture in Mimicking Hepatic Lobule-like Tissues.Micromachines · 2021Article
- Bio-assembling and Bioprinting for Engineering Microvessels from the Bottom Up.International journal of bioprinting · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is urgent demand for biologically compatible vascular grafts for both adult and pediatric patients. The utility of conventional nonbiodegradable materials is limited because of their thrombogenicity and inability to grow, while autologous vascular grafts involve considerable disadvantages, including the invasive procedures required to obtain these healthy vessels from patients and insufficient availability in patients with systemic atherosclerosis. All of these issues could be overcome by tissue-engineered vascular grafts (TEVGs). A large body of evidence has recently emerged in support of TEVG technologies, introducing diverse cell sources (e.g., somatic cells and stem cells) and novel fabrication methods (e.g., scaffold-guided and self-assembled approaches). Before TEVG can be applied in a clinical setting, however, several aspects of the technology must be improved, such as the feasibility of obtaining cells, their biocompatibility and mechanical properties, and the time needed for fabrication, while the safety of supplemented materials, the patency and nonthrombogenicity of TEVGs, their growth potential, and the long-term influence of implanted TEVGs in the body must be assessed. Although recent advances in TEVG fabrication have yielded promising results, more research is needed to achieve the most feasible methods for generating optimal TEVGs. This article reviews multiple aspects of TEVG fabrication, including mechanical requirements, extracellular matrix components, cell sources, and tissue engineering approaches. The potential of periodic hydrostatic pressurization in the production of scaffold-free TEVGs with optimal elasticity and stiffness is also discussed. In the future, the integration of multiple technologies is expected to enable improved TEVG performance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.